European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Padcev, enfortumab vedotin, Date of authorisation: 13/04/2022, Revision: 11, Status: Authorised

Submitted by Anonymous (not verified) on 16 October 2026 - 16:05

Human medicines European public assessment report (EPAR): Padcev, enfortumab vedotin, Date of authorisation: 13/04/2022, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Cibinqo, abrocitinib, Date of authorisation: 09/12/2021, Revision: 21, Status: Authorised

Submitted by Anonymous (not verified) on 16 October 2026 - 15:15

Human medicines European public assessment report (EPAR): Cibinqo, abrocitinib, Date of authorisation: 09/12/2021, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Idefirix, imlifidase, Date of authorisation: 25/08/2020, Revision: 11, Status: Authorised

Submitted by Anonymous (not verified) on 16 October 2026 - 15:02

Human medicines European public assessment report (EPAR): Idefirix, imlifidase, Date of authorisation: 25/08/2020, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Plegridy, peginterferon beta-1a, Date of authorisation: 18/07/2014, Revision: 31, Status: Authorised

Submitted by Anonymous (not verified) on 16 October 2026 - 14:47

Human medicines European public assessment report (EPAR): Plegridy, peginterferon beta-1a, Date of authorisation: 18/07/2014, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): HyQvia, human normal immunoglobulin, Date of authorisation: 16/05/2013, Revision: 27, Status: Authorised

Submitted by Anonymous (not verified) on 16 October 2026 - 14:33

Human medicines European public assessment report (EPAR): HyQvia, human normal immunoglobulin, Date of authorisation: 16/05/2013, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Date of authorisation: 08/01/2018, Revision: 28, Status: Authorised

Submitted by Anonymous (not verified) on 16 October 2026 - 14:20

Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Date of authorisation: 08/01/2018, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Saphnelo, anifrolumab, Date of authorisation: 14/02/2022, Revision: 12, Status: Authorised

Submitted by Anonymous (not verified) on 16 October 2026 - 14:00

Human medicines European public assessment report (EPAR): Saphnelo, anifrolumab, Date of authorisation: 14/02/2022, Revision: 12, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More